title: Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response.
abstract: We studied nine patients affected by chronic myeloid leukemia (CML Ph+ and bcr-abl positive) and treated with alpha-interferon (alpha-INF) in order to: first, to evaluate the feasibility of a mobilization of peripheral blood stem cells induced by granulocyte-colony-stimulating factor (G-CSF) and the contamination by Ph+ cells and second, to quantify the amount of bcr-abl leukemia associated transcript by a quantitative assay during mobilization procedures, and post mobilization follow-up. Eight achieved a complete karyotypic remission before mobilization obtained with discontinuation of alpha-INF for few days and G-CSF at a dosage of 15 microg/kg/day for 5-7 consecutive days. By quantitative-competitive polymerase chain reaction (QC-PCR) assay, all the leukaphereses and bone marrow samples during post mobilization follow up were studied to determine the amount of bcr-abl transcript. Karyotypic and molecular analysis on evaluable leukapheresis showed that all the harvests were Ph negative and bcr-abl positive: in seven cases the levels of bcr-abl transcript were higher or equal to the pre-apheresis status. In three out of four patients, who underwent more than one leukapheresis procedure, we noticed a decreasing amount of bcr-abl contamination from the first to the last apheresis. Our results suggest that in patients who achieved a complete or major cytogenetic conversion with alpha-INF, it is possible to obtain a sufficient amount of PBSC for autografting by leukapheresis following priming G-CSF therapy and that the amount of neoplastic transcript does not seem to increase.
authors.affiliation: Institute of Hematology and Medical Oncology Seràgnoli, S. Orsola Hospital, University of Bologna, Italy. gmartino@kaiser.alma.unibo.it
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: V
authors.initials: V
authors.lastname: Montefusco
authors.forename: M
authors.initials: M
authors.lastname: Amabile
authors.forename: R M
authors.initials: RM
authors.lastname: Lemoli
authors.forename: C
authors.initials: C
authors.lastname: Terragna
authors.forename: N
authors.initials: N
authors.lastname: Testoni
authors.forename: E
authors.initials: E
authors.lastname: Ottaviani
authors.forename: G
authors.initials: G
authors.lastname: Rosti
authors.forename: A
authors.initials: A
authors.lastname: de Vivo
authors.forename: S
authors.initials: S
authors.lastname: Rizzi
authors.forename: D
authors.initials: D
authors.lastname: Russo
authors.forename: M
authors.initials: M
authors.lastname: Bregoli
authors.forename: S
authors.initials: S
authors.lastname: Tura
mesh_terms: D000293:Adolescent; D000328:Adult; D001781:Blood Component Removal; D020732:Cytogenetic Analysis; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D012334:RNA, Neoplasm / Q000097:blood
chemical_list: D012334:RNA, Neoplasm; D016179:Granulocyte Colony-Stimulating Factor; D016044:Fusion Proteins, bcr-abl